Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 16/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | AHR | P35869 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29492688 | 1.00 | PARP1 (1.00) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL22457401 | 0.77 | PARP1 (0.62) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL14027180 | 0.77 | PARP1 (0.62) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL307689 | 0.77 | PARP1 (0.62) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL1536658 | 0.75 | PARP1 (0.60) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL31743106 | 0.75 | PARP1 (0.60) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL12463821 | 0.75 | PARP1 (0.60) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL29519573 | 0.75 | PARP1 (1.00) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL832144 | 0.75 | PARP1 (0.60) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL30033470 | 0.75 | PARP1 (0.60) | PARP1ALDH1A1HSD17B10KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-11 | — | — | US | disclosed |
| EP-4558483-A1 | NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| US-20250009723-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | FIMBRION THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) | 2024-10-24 | — | — | US | disclosed |
| EP-3558969-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-18 | — | — | EP | disclosed |
| EP-4378938-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-06-05 | — | — | EP | disclosed |
| CN-117642393-A | Novel PARP7 inhibitor and application thereof | 上海齐鲁制药研究中心有限公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2024038282-A1 | 2-AZA- AND 2-OXABICYCLO[2.1.1]HEXANE DERIVATIVES AS FACTOR XIIA ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024017856-A1 | NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20090312276-A1 | Compositions and Methods for Treating Cancer | IMMUNOGENESIS, INC. | 2009-12-17 | — | — | US | disclosed |
| US-7550496-B2 | Compositions and methods for treating cancer | THRESHOLD PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20080132458-A1 | Hypoxia-Activated Anti-Cancer Agents | THRESHOLD PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20060258656-A1 | Compositions and methods for treating cancer | THRESHOLD PHARMACEUTICALS, INC. (US) | 2006-11-16 | — | — | US | disclosed |
| EP-1622608-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Threshold Pharmaceuticals, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2005086951-A2 | HYPOXIA-ACTIVATED ANTI-CANCER AGENTS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2004087075-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | OPRM1, OPRK1, OPRD1 | PARP1 4602/4885ALDH1A1 891/4885HSD17B10 301/4885 |
| US-20250009723-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | MAN2B2, MAN2A1, MANBA | PARP1 1886/4885ALDH1A1 1880/4885HSD17B10 3817/4885 |
| US-20060258656-A1 | Compositions and methods for treating cancer | HIF1A, HIF1AN, EGLN3 | PARP1 711/4885ALDH1A1 306/4885HSD17B10 1716/4885 |
| US-20080132458-A1 | Hypoxia-Activated Anti-Cancer Agents | HIF1AN, HIF1A, HYOU1 | PARP1 495/4885ALDH1A1 1203/4885HSD17B10 3426/4885 |
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | PARP1 699/4885ALDH1A1 4167/4885HSD17B10 2842/4885 |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | PDE3A, PDE2A, PDE3B | PARP1 1433/4885ALDH1A1 190/4885HSD17B10 252/4885 |
| US-20090312276-A1 | Compositions and Methods for Treating Cancer | HIF1A, HIF1AN, EGLN3 | PARP1 711/4885ALDH1A1 306/4885HSD17B10 1716/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | PARP1 328/4885ALDH1A1 2267/4885HSD17B10 684/4885 |
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | PARP6, PARP4, PARP3 | PARP1 6/4885ALDH1A1 549/4885HSD17B10 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.